meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
Company profile
Ticker
MGTX
Exchange
Website
CEO
Alexandria Forbes
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
BRI-Alzan, Inc. • MeiraGTx B.V. • MeiraGTx Netherlands B.V. • MeiraGTx Limited • MeiraGTx, LLC • MeiraGTx UK Limited • MeiraGTx UK II Limited • MeiraGTx Ireland • MeiraGTx Neurosciences, Inc. • MeiraGTx Bio Inc. ...
MGTX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K/A
Departure of Directors or Certain Officers
16 Apr 24
10-K
2023 FY
Annual report
15 Mar 24
8-K
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
14 Mar 24
8-K
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
13 Feb 24
EFFECT
Notice of effectiveness
2 Jan 24
CORRESP
Correspondence with SEC
27 Dec 23
UPLOAD
Letter from SEC
27 Dec 23
Latest ownership filings
4
Alexandria Forbes
8 Apr 24
4
Alexandria Forbes
14 Mar 24
4
Richard Giroux
4 Mar 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
Prosight Management, LP
13 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4/A
Robert K Zeldin
18 Jan 24
4
Richard Giroux
17 Jan 24
4
Robert K Zeldin
17 Jan 24
4
Alexandria Forbes
17 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 64.40 mm | 64.40 mm | 64.40 mm | 64.40 mm | 64.40 mm | 64.40 mm |
Cash burn (monthly) | 9.46 mm | 4.19 mm | 10.92 mm | 11.20 mm | 8.14 mm | 8.92 mm |
Cash used (since last report) | 65.07 mm | 28.84 mm | 75.14 mm | 77.04 mm | 56.00 mm | 61.40 mm |
Cash remaining | -666.39 k | 35.56 mm | -10.74 mm | -12.64 mm | 8.41 mm | 3.00 mm |
Runway (months of cash) | -0.1 | 8.5 | -1.0 | -1.1 | 1.0 | 0.3 |
Institutional ownership, Q2 2023
62.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 79 |
Opened positions | 8 |
Closed positions | 19 |
Increased positions | 30 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 249.66 bn |
Total shares | 39.97 mm |
Total puts | 29.60 k |
Total calls | 9.10 k |
Total put/call ratio | 3.3 |
Largest owners | Shares | Value |
---|---|---|
Perceptive Advisors | 11.33 mm | $76.15 bn |
JNJ Johnson & Johnson | 6.64 mm | $44.63 bn |
Adage Capital Partners GP, L.L.C. | 4.67 mm | $31.39 bn |
Prosight Management | 4.08 mm | $27.41 bn |
683 Capital Management | 2.46 mm | $16.52 bn |
BLK Blackrock | 2.10 mm | $14.11 bn |
ARE Alexandria Real Estate Equities | 1.98 mm | $47.07 mm |
KDMN Kadmon | 697.74 k | $10.56 mm |
Royce & Associates | 677.72 k | $4.55 bn |
STT State Street | 540.49 k | $3.63 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Forbes Alexandria | Ordinary Shares | Gift | Dispose G | No | No | 0 | 1,000 | 0.00 | 1,372,504 |
12 Mar 24 | Forbes Alexandria | Ordinary Shares | Gift | Dispose G | No | No | 0 | 2,000 | 0.00 | 1,373,504 |
29 Feb 24 | Giroux Richard | Ordinary Shares | Gift | Dispose G | No | No | 0 | 13,500 | 0.00 | 840,426 |
17 Jan 24 | Naylor Stuart | Restricted Share Units Ordinary Shares | Grant | Acquire A | No | No | 0 | 150,000 | 0.00 | 150,000 |
17 Jan 24 | Robert J Wollin | Restricted Share Units Ordinary Shares | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 100,000 |
14 Jan 24 | Naylor Stuart | Ordinary Shares | Payment of exercise | Dispose F | No | No | 6.36 | 11,163 | 71.00 k | 564,329 |
14 Jan 24 | Naylor Stuart | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 23,750 | 0.00 | 575,492 |
14 Jan 24 | Naylor Stuart | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 23,750 | 0.00 | 23,750 |
14 Jan 24 | Robert J Wollin | Ordinary Shares | Payment of exercise | Dispose F | No | No | 6.36 | 2,644 | 16.82 k | 15,137 |
14 Jan 24 | Robert J Wollin | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 5,000 | 0.00 | 17,781 |
Press releases
MeiraGTx to Participate in Upcoming Investor Conferences
24 Apr 24
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
18 Apr 24
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
13 Feb 24
Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors
1 Feb 24